Market exit and product discontinuation

Market exit and product discontinuation

Managed Access Program to find suitable replacement therapies

Market exit of a drug is a valid strategic direction for biopharmaceutical companies. Therapy discontinuation could potentially result in an unmet medical need for those patients unable to find suitable replacement therapies. The solution for pharmaceutical manufacturers to mitigate such implications for patients, is to put in place a Managed Access Program. This alternative route will allow patients to have access to the required medicine in an unlicensed status.

farmamondo-unlicensed-medicines-graphic3

Contact Us

Managed Access Program to find suitable replacement therapies

Market exit of a drug is a valid strategic direction for biopharmaceutical companies. Therapy discontinuation could potentially result in an unmet medical need for those patients unable to find suitable replacement therapies. The solution for pharmaceutical manufacturers to mitigate such implications for patients, is to put in place a Managed Access Program. This alternative route will allow patients to have access to the required medicine in an unlicensed status.

Contact Us

HOW WE PROVIDE ACCESS 

Staggered launch of
new products

While market access plans of research-based pharmaceutical companies may not cover all countries equally, their patient-centric launch strategies should allow access for patients with

Shortages of established
products

Medicine shortages are a growing and complex global challenge. Shortages of essential drugs are becoming increasingly frequent globally, burdening health systems with additional costs and posing

Market exit and product

discontinuation

Market exit of a drug is a valid strategic direction for biopharmaceutical companies. Therapy discontinuation could potentially result in an unmet medical need for those patients unable to find

HOW WE PROVIDE ACCESS 

Staggered launch of
new products

While market access plans of research-based pharmaceutical companies may not cover all countries equally, their patient-centric launch strategies should allow access for patients with unmet medical needs also in non-launched countries.

Shortages of established
products

Medicine shortages are a growing and complex global challenge. Shortages of essential drugs are becoming increasingly frequent globally, burdening health systems with additional costs and posing risks to the health of patients who fail to receive the medicines they need.

Market exit & Life
cycle management

Market exit of a drug is a valid strategic direction for biopharmaceutical companies. Therapy discontinuation could potentially result in an unmet medical need for those patients unable to find suitable replacement therapies.

FOLLOW US ON